Skip to Content

Spinraza (nusinersen) Disease Interactions

There are 2 disease interactions with Spinraza (nusinersen):

Moderate

Nusinersen (Includes Spinraza) ↔ Bleeding Risks

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding, Coagulation Defect

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been reported after administration of some antisense oligonucleotides. In one clinical study, platelet levels below the lower limit of normal were observed in 6 of 56 (11%) nusinersen-treated patients compared to 0 of 28 sham-procedure control patients who had normal or above normal platelet levels at baseline. No patient had a platelet count less than 50,000 cells/microliter, however, and no patient developed a sustained low platelet count despite continued drug exposure. Given the potential for increased risk of bleeding complications, therapy with nusinersen should be administered cautiously in patients with active bleeding or coagulation abnormalities. Platelet counts and coagulation laboratory testing should be performed at baseline and prior to each administration of nusinersen and as clinically needed.

Moderate

Nusinersen (Includes Spinraza) ↔ Renal Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Caution is advised if used in patients with renal impairment. The manufacturers recommend to conduct quantitative spot urine protein- testing (preferable using a first morning urine specimen) at baseline and prior to each dose of nusinersen. A urine protein concentration greater than 0.2 g/L merits retesting and further evaluation.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide